Recent compounds for immunosuppression and experimental therapies for acute graft-versus-host disease

Maria Michael, Avichai Shimoni, Arnon Nagler*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

7 Scopus citations

Abstract

Acute graft-versus-host disease (GVHD) is a major source of morbidity and mortality after allogeneic stem cell transplantation. Therapy of established acute GVHD depends heavily on corticosteroids, which have limited efficacy and are considerably toxic. It is still a matter of debate whether there is an alternative therapy to corticosteroids. Second-line treatment for acute GVHD after failure of steroids is not well substantiated due to the lack of controlled studies. This review examines the current treatment for acute GVHD, as well as novel therapeutics, such as cellular approaches (e.g., adoptive transfer of mesenchymal stem cells) and enhancement of regulatory T cells (e.g., photopheresis). These approaches avoid the toxicity of generalized immuno-suppression and are likely to play a prominent future role in acute GVHD therapy.

Original languageEnglish
Pages (from-to)44-50
Number of pages7
JournalIsrael Medical Association Journal
Volume15
Issue number1
StatePublished - Jan 2013

Keywords

  • Allogeneic stem cell transplantation
  • Bone marrow transplantation
  • Graft-versus-host disease (GVHD)

Fingerprint

Dive into the research topics of 'Recent compounds for immunosuppression and experimental therapies for acute graft-versus-host disease'. Together they form a unique fingerprint.

Cite this